The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Treatment options for CLL patients with poor prognostic markers
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses treatment options for chronic lymphocytic leukemia (CLL) patients with poor prognostic markers such as TP53 aberration and unmutated IgHV status. Dr Al-Sawaf highlights both fixed duration approaches and continuous treatment as options for these patients, and the need for head-to-head comparison trials to better understand which option to choose. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
